Mountain View, United States
AbTherx, with the slogan "Creating Cures", is setting new benchmarks in the biopharmaceutical sector by leveraging cutting-edge technologies that expedite therapeutic antibody discovery. Founded in 2023, the company has forged an exclusive partnership with Gilead Sciences to launch Atlas™ Mice, transgenic technologies noted for their exceptional performance and freedom to operate (FTO).
With over two decades of experience, AbTherx's team has spearheaded over 1,000 antibody discovery campaigns, resulting in 13 marketed therapeutics. The company's dedication to innovation is evident in its robust portfolio that addresses even the most formidable challenges in drug development.
Their commitment to accessibility is reflected through flexible partnership models, catering to diverse drug developers. While AbTherx is a new entrant on paper, it rides on a history steeped in expertise, positioning it as a prime candidate for investment to those interested in revolutionary healthcare solutions.
